Federal Court Dismisses Challenge to Constitutionality of Federal Government's Drug Price Watchdog
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 07/06/16 -- Patented Medicine Prices Review Board
In a decision dated June 23, 2016, Canada's Federal Court dismissed a constitutional challenge brought against the Patented Medicine Prices Review Board (PMPRB), an agency created by the federal government to protect consumers from excessively priced patented medicines.
The challenge was brought in September 2015 by Alexion Pharmaceuticals Inc., which sells the patented drug Soliris. This drug is currently the subject of a legal proceeding before the PMPRB into allegations that the drug is priced excessively in Canada.
In dismissing Alexion's case, the Federal Court agreed with the Attorney General of Canada that the challenge was "bereft of any chance of success" given that the constitutionality of the PMPRB and its price regulation powers have already been affirmed on multiple occasions by Canadian court decisions.
Quick Facts
Additional Links
- (Patented Medicine Prices Review Board)
Follow us on Twitter:
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
TTY (telecommunications device for the hearing impaired)
613-957-4373
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.07.2016 - 15:00 Uhr
Sprache: Deutsch
News-ID 481861
Anzahl Zeichen: 0
contact information:
Town:
OTTAWA, ONTARIO
Kategorie:
National
Diese Pressemitteilung wurde bisher 343 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Federal Court Dismisses Challenge to Constitutionality of Federal Government's Drug Price Watchdog"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
